Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders

 Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders

Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders

Shots

  • VCNDD and BI enters into two agreement for the development and commercialization of two small molecules targeting GPCRs for neuropsychiatric disorders
  • The focus of the agreement is to develop and expand therapies for neurological conditions including maladaptive brain circuitry
  • GPCRs(G-protein coupled receptors) are protein involved in regulation of brain circuit functions targeting schizophrenia, further helps in activatingsignal transduction pathways

Click here to read full press release/ article | Ref: VCNDD | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post